Medtronic plc
MDT · NYSE · Healthcare
$0.13 today
- Mkt cap $102.97B
- P/E 21.5
- Day $79.26 – $80.45
Confidence
High conviction
The read
Medtronic reports in-line Q4 EPS of $1.55; shares slightly up post-earnings
Medtronic's Q4 EPS came in at $1.55, marginally below the $1.56 estimate, with shares rising 0.1% post-report. Guidance tone was neutral, reflecting steady revenue growth but ongoing risks from the diabetes unit spinoff and neuromodulation recall.
Confidence note: EPS reported in-line with consensus and clear risks identified; catalyst timeline and risks well defined for actionable scenarios.
What happened
Earnings print
Guidance
Price reaction
Street narrative
So what
What changed
What the market is pricing
Fundamental takeaway
Next 30–90 days
Spinoff proceeds smoothly, neuromodulation recall impact diminishes, enabling renewed growth acceleration.
- boltPositive updates on diabetes unit spinoff integration by Q3 earnings.
- boltResolution or mitigation of neuromodulation recall issues within 90 days.
Steady revenue growth continues with manageable spinoff and recall headwinds, EPS growth remains moderate.
- boltStable guidance with no major changes in next earnings report.
- boltNo new significant recall or spinoff setbacks.
Spinoff complications and recall issues intensify, pressuring growth and investor confidence, leading to earnings misses.
- boltNegative guidance revision in next quarter.
- boltMaterial delays or financial impact from spinoff or recall.
What to do
If you hold it
If you're watching
Keep on your radar
- Next earnings report expected by Q3 2026 for spinoff and guidance updates.
- Management commentary on diabetes unit spinoff execution progress.
- Neuromodulation recall status and any regulatory developments.
- Dividend sustainability given 76% payout ratio and cash flow trends.